Under the deal terms, Novartis will pay $7 per share in cash upfront, or about $800 million, and another $7 per share to Regulus shareholders if the lead drug candidate, farabursen, gets ...

Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash upfront through a subsidiary ...

Novartis NOVN0.71%increase; green up pointing triangle has agreed to acquire Regulus Therapeutics RGLS-0.38%decrease; red down pointing triangle for a total equity value of up to roughly $1.7 ...

Novartis to acquire Regulus for $7/share upfront, a 108% premium to April 29 close and 274% over 60-day VWAP. The total deal could reach $1.7 billion if farabursen gains regulatory approval, with ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novartis will pay $800 million upfront to acquire Regulus Therapeutics, a San Diego biotechnology company ...

You can reach Jason on Signal at JasonMast.05. Novartis said Wednesday it would buy Regulus Therapeutics and its experimental kidney drug for $800 million upfront. The immediate payout is more ...

Novartis (NYSE:NVS) has agreed to acquire biopharmaceutical firm Regulus Therapeutics (NASDAQ:RGLS) for an initial payment of $7.00 a share in cash at closing, or $0.8B. The upfront cash portion ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals get in the way of its progress. With recent indication additions, breast ...

April 30 (Reuters) - Novartis (NOVN.S), opens new tab has agreed to buy Regulus Therapeutics (RGLS.O), opens new tab for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...